Yukuan Tang

Dr. Yukuan Tang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Stem Cell Research
Verified
Journal Article
Open access
CHChen Huang
Chen Huang
WLWenfeng Luo
Wenfeng Luo
QWQian Wang
Qian Wang
YYYufeng Ye
Yufeng Ye
JFJinghui Fan
Jinghui Fan
YTYukuan Tang
Yukuan Tang
Diabetic foot is caused by ischemic disease of lower extremities of diabetic patients, and the effective therapy is very limited. Mesenchymal stem cells (MSCs) based cell therapy had been developed into a new treatment strategy for diabetic foot clinically. However, the underlying molecular mechanism remains to be fully addressed. Exosomes (extracellular vesicles) secreted by MSCs may play crucial role in the processes of MSCs mediated inhibition of inflammatory microenvironment as well as pro-angiogenesis of ischemic tissue of diabetic foot. Exosomes were isolated from MSCs using ultracentrifugation, and further characterized by the nanoparticle tracking analyzer and flow cytometry. Moreover, RNA sequencing, Western Blot, in vitro cell proliferation, in vivo pro-angiogenesis, as well as ischemic repairment of diabetic foot through rat model were performed to evaluate exosome physiological functions. We found that inflammatory cytokines (tumor necrosis factor α and interleukin-6) and vascularcelladhesion molecule-1 induced MSCs to secrete exosomes heterogeneously, including exosome size and quantity. Through RNA sequencing, we defined a new proangiogenic miRNA, miRNA-21-5p. Further knockdown and overexpression of miRNA-21-5p by manipulating MSCs validated the biological activity of exosome miRNA-21-5p, including in vitro cell proliferation, in vivo pro-angiogenesis in Chick Chorioallantoic Membrane (CAM) assay, and in vivo pro-angiogenesis experiments (tissue injury and repair) in diabetic rat models. Furthermore, we discovered that exosomemiRNA-21-5p promoted angiogenesis through upregulations of vascular endothelial growth factor receptor (VEGFR) as well as activations of serine/threonine kinase (AKT) and mitogen-activated protein kinase (MAPK). Together, our work suggested miRNA-21-5p could be a novel mechanism by which exosomes promote ischemic tissue repair and angiogenesis. Meanwhile, miRNA-21-5p could be potentially developed into a new biomarker for exosomes of MSCs to treat diabetic foot. miRNA-21-5p is a new biomarker and a novel mechanism by which exosomes promote ischemic tissue repair and angiogenesis of diabetic foot. Our work could not only provide new scientific evidences for revealing pro-angiogenesis mechanism of MSCs, but also eventually benefit MSCs-based clinical therapy for diabetic foot of diabetes patients.

18 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CHchen huang
chen huang
WHWentao Huang
Wentao Huang
LZLifen Zhang
Lifen Zhang
CZChunyu Zhang
Chunyu Zhang
CZChengqian Zhou
Chengqian Zhou
YTYukuan Tang
Yukuan Tang
Atherosclerosis is the leading cause of global morbidity and mortality. Its therapy requires research in several areas, such as diagnosis of early arteriosclerosis, improvement of the pharmacokinetics and bioavailability of rapamycin as its therapeutic agents. Here, we used the targeting peptide VHPKQHR (VHP) (or fluorescent reagent) to modify the phospholipid molecules to target vascular cell adhesion molecule-1 (VCAM-1) and loaded ultrasmall paramagnetic iron oxide (USPIO/Fe3O4) plus rapamycin (Rap) to Rap/Fe3O4@VHP-Lipo (VHPKQHR-modified magnetic liposomes coated with Rap). This nanoparticle can be used for both the diagnosis and therapy of early atherosclerosis. We designed both an ex vivo system with mouse aortic endothelial cells (MAECs) and an in vivo system with ApoE knockout mice to test the labeling and delivering potential of Rap/Fe3O4@VHP-Lipo with fluorescent microscopy, flow cytometry and MRI. Our results of MRI imaging and fluorescence imaging showed that the T2 relaxation time of the Rap/Fe3O4@VHP-Lipo group was reduced by 2.7 times and 1.5 times, and the fluorescence intensity increased by 3.4 times and 2.5 times, respectively, compared with the normal saline group and the control liposome treatment group. It showed that Rap/Fe3O4@VHP-Lipo realized the diagnosis of early AS. Additionally, our results showed that, compared with the normal saline and control liposomes treatment group, the aortic fluorescence intensity of the Rap/Fe3O4@VHP-Lipo treatment group was significantly weaker, and the T2 relaxation time was prolonged by 8.9 times and 2.0 times, indicating that the targeted diagnostic agent detected the least plaques in the Rap/Fe3O4@VHP-Lipo treatment group. Based on our results, the synthesized theragnostic Rap/Fe3O4@VHP-Lipo serves as a great label for both MRI and fluorescence bimodal imaging of atherosclerosis. It also has therapeutic effects for the early treatment of atherosclerosis, and it has great potential for early diagnosis and can achieve the same level of therapy with a lower dose of Rap.

26 October 2019 in World Journal of Stem Cells
Verified
Journal Article
Open access
CHChen Huang
Chen Huang
WLWen-Feng Luo
Wen-Feng Luo
YYYu-Feng Ye
Yu-Feng Ye
LLLi Lin
Li Lin
ZWZhe Wang
Zhe Wang
YTYukuan Tang
Yukuan Tang
Characterization of inflammatory factor-induced changes in mesenchymal stem cell exosomes and sequencing analysis of exosomal microRNAs

28 February 2022 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
CZChunyu Zhang
Chunyu Zhang
WHWentao Huang
Wentao Huang
CHChen Huang
Chen Huang
CZChengqian Zhou
Chengqian Zhou
YTYukuan Tang
Yukuan Tang
WCWenli chen
Wenli chen
Magnetic resonance imaging (MRI) could be the ideal diagnostic modality for early rheumatoid arthritis (RA). Vascular cell adhesion molecule-1 (VCAM-1) is highly expressed in synovial locations in patients with RA, which could be a potential target protein for RA diagnosis. The peptide VHPKQHR (VHP) has a high affinity to VCAM-1. To make the contrast agent to target RA at an early stage, we used VHP and ultrasmall paramagnetic iron oxide (USPIO) to synthesize UVHP (U stands for USPIO) through a chemical reaction with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide. The size of UVHP was 6.7 nm; the potential was −27.7 mV, and ther2/r1value was 1.73. Cytotoxicity assay exhibited that the cell survival rate was higher than 80% at even high concentrations of UVHP (Fe concentration 200 µg/mL), which showed the UVHP has low toxicity. Compared with no TNF-α stimulation, VCAM-1 expression was increased nearly 3-fold when mouse aortic endothelial cells (MAECs) were stimulated with 50 ng/mL TNF-α; cellular Fe uptake was increased very significantly with increasing UVHP concentration under TNF-α treatment; cellular Fe content was 17 times higher under UVHP with Fe concentration 200 µg/mL treating MAECs. These results indicate that UVHP can target overexpression of VCAM-1 at the cellular level. RA mice models were constructed with adjuvant-induced arthritis.In vivoMRI and biodistribution results show that the signal intensity of knee joints was increased significantly and Fe accumulation in RA model mice compared with normal wild-type mice after injecting UVHP 24 h. These results suggest that we have synthesized a simple, low-cost, and less toxic contrast agent UVHP, which targeted VCAM-1 for early-stage RA diagnosis and generates high contrast in T1-weighted MRI.

25 January 2024 in Biomedical Materials
Verified
Journal Article
Open access
PDF file
CHChen Huang
Chen Huang
WHWentao Huang
Wentao Huang
YMYixuan Meng
Yixuan Meng
CZChengqian Zhou
Chengqian Zhou
XWXiaozhuan Wang
Xiaozhuan Wang
YTYukuan Tang
Yukuan Tang
Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of cholesterol within the arterial wall. Its progression can be monitored via magnetic resonance imaging (MRI). Ultrasmall Superparamagnetic Particles of Iron Oxide (USPIO) (<5 nm) have been employed as T1 contrast agents for MRI applications. In this study, we synthesized USPIO with an average surface carboxylation of approximately 5.28 nm and a zeta potential of −47.8 mV. These particles were phagocytosed by mouse aortic endothelial cells (USPIO-MAECs) and endothelial progenitor cells (USPIO-EPCs), suggesting that they can be utilized as potential contrast agent and delivery vehicle for the early detection of atherosclerosis. However, the mechanism by which this contrast agent is delivered to the plaque remains undetermined. Our results demonstrated that with increasing USPIO concentration during 10–100 μg ml−1, consistent change appeared in signal enhancement on T1-weighted MRI. Similarly, T1-weighted MRI of MAECs and EPCs treated with these concentrations exhibited a regular change in signal enhancement. Prussian blue staining of USPIO revealed substantial absorption into MAECs and EPCs after treatment with 50 μg ml−1 USPIO for 24 h. The iron content in USPIO-EPCs was much higher (5 pg Fe/cell) than in USPIO-MAECs (0.8 pg Fe/cell). In order to substantiate our hypothesis that CD40 protein on the cell surface facilitates migration towards inflammatory cells, we utilized AuNPs-PEI (gold nanoparticles-polyethylenimine) carrying siRNACD40 to knockout CD40 expression in MAECs. It has been documented that gold nanoparticle-oligonucleotide complexes could be employed as intracellular gene regulation agents for the control of protein level in cells. Our results confirmed that macrophages are more likely to bind to MAECs treated with AuNPs-PEI-siRNANC (control) for 72 h than to MAECs treated with AuNPs-PEI-siRNACD40 (reduced CD40 expression), thus confirming CD40 targeting at the cellular level. When USPIO-MAECs and MAECs (control) were delivered to mice (high-fat-fed) via tail vein injection respectively, we observed a higher iron accumulation in plaques on blood vessels in high-fat-fed mice treated with USPIO-MAECs. We also demonstrated that USPIO-EPCs, when delivered to high-fat-fed mice via tail vein injection, could indeed label plaques by generating higher T1-weighted MRI signals 72 h post injection compared to controls (PBS, USPIO and EPCs alone). In conclusion, we synthesized a USPIO suitable for T1-weighted MRI. Our results have confirmed separately at the cellular and tissue and in vivo level, that USPIO-MAECs or USPIO-EPCs are more accessible to atherosclerotic plaques in a mouse model. Furthermore, the high expression of CD40 on the cell surface is a key factor for targeting and USPIO-EPCs may have potential therapeutic effects.

15 October 2025 in World Journal of Diabetes
Verified
Journal Article
Open access
CHChen Huang
Chen Huang
HLHe-Zhu Liu
He-Zhu Liu
JLJia-Bin Liang
Jia-Bin Liang
WZWei Zhao
Wei Zhao
YWYan-Sheng Wang
Yan-Sheng Wang
YTYukuan Tang
Yukuan Tang
BACKGROUND Diabetic foot ulcers (DFUs) affect approximately 18.6 million people worldwide every year. Patients with DFU often present with symptoms such as lower limb infections, ulcers, and deep tissue damage. Platelet-rich plasma (PRP) is a concentrated platelet product that can trigger the release of growth factors and cytokines, which stimulate tissue healing and regeneration and thus alleviates DFU. At present, no comprehensive study has been conducted to verify the effect of PRP in both in vitro and clinical settings for treating DFUs. AIM To perform the in vitro and clinical evaluation of PRP combined with endovascular angioplasty in treating diabetic foot. METHODS This study focused on both in vitro and clinical settings. In the in vitro study, human umbilical vein endothelial cells (HUVECs), human dermal fibroblasts (HSFs), and human immortalized keratinocytes (HaCaTs) were treated with PRP. Experiments involving proliferation, migration, tubule formation, and angiogenesis signaling pathways were conducted. In this clinical study, patients who visited the Affiliated Panyu Central Hospital of Guangzhou Medical University from 2020 to 2024 and met enrollment criteria were randomly assigned to 2 groups using prospective block randomization. In the control group, the DFU was treated with endovascular angioplasty and wound debridement. In the PRP + endovascular angioplasty group, PRP was evenly used on the surface of superficial ulcers, followed by endovascular angioplasty to treat vascular occlusion. The key outcomes were measured, including the Rutherford scale, Wagner scale, foot skin temperature, and ulcer repair area before and after treatment. RESULTS In the in vitro study, 6% PRP could promote the proliferation and migration of HUVECs, HSFs, and HaCaTs in a high-glucose environment. Additionally, it promoted tubule formation in HUVECs by activating signaling proteins such as Ak strain transforming and extracellular regulated protein kinases 1/2. In the clinical study, a total of 208 patients participated. After 12 months of treatment, the ulcer repair area (14.95 ± 0.16 cm2) and ulcer healing rate were improved in the PRP + endovascular angioplasty group than in the control group (P < 0.05). CONCLUSION The combination of 6% activated PRP and endovascular angioplasty may improve the microcirculation and tissue repair in DFUs. This study offers a novel treatment option for patients with diabetic foot.